Trials / Unknown
UnknownNCT04515706
Iguratimod in Systemic Sclerosis
Safety, Tolerability, Efficacy of Iguratimod in Systemic Sclerosis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of iguratimod in adult subjects with diffuse cutaneous systemic sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iguratimod | Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect. |
| DRUG | Placebo | Placebo of Iguratimod |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2023-01-31
- Completion
- 2024-01-31
- First posted
- 2020-08-17
- Last updated
- 2020-08-17
Source: ClinicalTrials.gov record NCT04515706. Inclusion in this directory is not an endorsement.